Agenda^*

View the conference agenda for WCMC, a dedicated forum for oncologists involved in the management of patients with cutaneous malignancies.

*Agenda subject to change.

Friday | September 30th, 2016

7:00-8:30 AM	Breakfast/Product Theater (non-CME/CE)
8:30-8:45 AM	Break (non-CME/CE)
8:45-9:00 AM	Welcome and Program Overview – Sanjiv Agarwala, MD
9:00-9:30 AM	An Overview of Cutaneous Malignancies: Outlining the Clinical Features of Melanoma and Nonmelanoma Skin Cancers – Scott Fosko, MD
9:30-10:30 AM	Melanoma Post-ASCO^® Update: What’s New and Exciting Immunotherapy – Michael Atkins, MD Targeted therapy – Michael Atkins, MD
10:30-10:45 AM	Break (non-CME/CE)
10:45-11:15 AM	Keynote Lecture: Making Sense of New Molecular Targets in Melanoma – Meenhard Herlyn, DVM, DSc
11:15 AM-12:15 PM	A Dermatologist’s Perspective on Cutaneous Malignancies Screening for melanoma and other cutaneous Malignancies – Axel Hauschild, MD Diagnosis of melanoma—advances in new technologies -Ashfaq Marghoob, MD
12:15-1:15 PM	Lunch/Product Theater (non-CME/CE)
1:15-1:30 PM	Break (non-CME/CE)
1:30-2:30 PM	Surgical and Locoregional Therapy in Melanoma Role of completion lymphadenectomy – Vernon Sondak, MD Intralesional therapy – Robert Andtbacka, MD, CM The changing role of surgery in the era of targeted therapy – Merrick Ross, MD Panel Discussion
2:30-2:45 PM	Molecular Biomarkers in Cutaneous Malignancies: Are We There Yet? – Ryan J. Sullivan, MD
2:45-3:45 PM	Making Sense of New Molecular Targets in Nonmelanoma Skin Cancers: Implications for Clinical Practice BCC: Jean Tang, MD, PhD CTCL: Madeleine Duvic, MD (“Targeted Antibodies in CTCL”) MCC: Shailender Bhatia, MD
3:45-4:30 PM	Emerging Concepts in BCC Therapeutic resistance – Dirk Schadendorf, MD New approaches to therapy – Alex Sekulic, MD, PhD
4:30-6:30 PM	Cocktail Reception/Networking (non-CME/CE)

Saturday | October 1st, 2016

7:00-8:00 AM	Breakfast/Product Theater (non-CME/CE)
8:00-8:15 AM	Break (non-CME/CE)
8:15-8:45 AM	Therapeutic Advances in CTCL in the Era of Molecular Targeting – Youn Kim, MD
8:45-9:30 AM	Metastatic Melanoma: Current Status of MAPK-Targeted Therapies – Jeff Sosman, MD
9:30-10:15 AM	Metastatic Melanoma: Current Status of Immune Checkpoint Inhibitors – Michael Postow, MD
10:15-10:30 AM	Break (non-CME/CE)
10:30–11:30 AM	Sequencing Therapies in Metastatic Melanoma Making sense of treatment algorithms – Jason Luke, MD Combining immunotherapy and targeted therapy in BRAF-mutated melanoma–are we there yet? – Michael Davies, MD, PhD
11:30 AM- 12:00 Noon	Emerging Targets in Melanoma: A Look to the Future Emerging immune checkpoint inhibitors – Igor Puzanov, MD, MSCI, FACP Other molecular/gene mutation targets – Dirk Schadendorf, MD
12:00-1:00 PM	Lunch/Product Theater (non-CME/CE)
1:00-1:15 PM	Break (non-CME/CE)
1:15-2:00 PM	Emerging Therapies for MCC – Paul Nghiem, MD, PhD
2:00 PM	Closing Remarks – Sanjiv Agarwala, MD